Hey all, welcome back to the Real Life Pharmacology podcast. I am your host, pharmacist Eric Christensen.

Thank you so much for listening today. Go check out Real Life Pharmacology.com.

Snag your free download, 31 page PDF on the top 200 drugs. I throw out important clinical real-world pearls on that educational piece as well as things that you're going to see come up on board exams and pharmacology exams and things like that.

So a great refresher if you're in practice or if you're in school, definitely a helpful resource to help you study and prepare for any exams you might be facing there.

So with that said, let's get into the drug of the day today, and that is Tolteridine.

Brand name of this medication is detrol.

There is a detrol LA as well. That's a long-acting or extended release product.

This class of medication, or the class that Tultaridine belongs to is the anticholinergic class,

and more specifically, it's a urinary anticholinergic.

And the diagnosis that we're going to most often treat with this medication is overactive bladder.

So from a mechanism of action standpoint,

Tultoridine is relatively selective for the inhibition of muscarinic receptors in the bladder and urinary tract area.

So it can definitely help kind of retain that volume in the bladder, which is going to help you go to the bathroom less, right?

So reduce that frequency of urination.

That's the primary goal.

Reduce symptoms of overactive bladder and symptoms of frequency.

From a dosing perspective, we've got the immediate release,

two milligrams twice a day, and then the long

acting is four milligrams once a day. Obviously, that's an advantage typically to give a medication

once a day versus twice a day. In my experience, it has been a little bit cheaper to use the

immediate release, so you might see that. Another

situation that you might see the immediate released used is in patients maybe that just have

...